247 related articles for article (PubMed ID: 33317345)
1. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A; Arenberger P; Balser S; Beissert S; Cauthen A; Czeloth N; Soung J; Jazayeri S; Weisenseel P; Jayadeva G
Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
[No Abstract] [Full Text] [Related]
2. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
Menter A; Cohen S; Kay J; Strand V; Gottlieb A; Hanauer S; Eduru SK; Buschke S; Lang B; Liesenfeld KH; Schaible J; McCabe D
Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
[TBL] [Abstract][Full Text] [Related]
3. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
[No Abstract] [Full Text] [Related]
7. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
[TBL] [Abstract][Full Text] [Related]
9. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H
BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Interchangeability of AVT02 and Humira
Feldman SR; Kay R; Reznichenko N; Sobierska J; Dias R; Otto H; Haliduola HN; Sattar A; Ruffieux R; Stroissnig H; Berti F
BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu C; Zhang F; Ding Y; Li Y; Zhao Y; Gu J; Guo S; Pan W; Jin H; Sun Q; Kang X; Yang Q; Jiang X; Song Z; Lu Q; Pang X; Kuang Y; Deng D; Li Y; Zhang C; Tao J; Xie L; Wang Y; Wang J; Wang G
Int Immunopharmacol; 2022 Nov; 112():109248. PubMed ID: 36126411
[TBL] [Abstract][Full Text] [Related]
13. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Narbutt J; Philipp S; Spelman L; Weglowska J; Zhang N; Strober B
J Am Acad Dermatol; 2017 Jun; 76(6):1093-1102. PubMed ID: 28291552
[TBL] [Abstract][Full Text] [Related]
14. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
Samtsov AV; Bakulev AL; Khairutdinov VR; Kokhan MM; Korotaeva TV; Minullin IK; Vylegzhanina OA; Dubenskiy VV; Khalilov BV; Khotko AA; Zykova OS; Chumachenko IV; Lukyanov AM; Artemeva AV; Pukhtinskaia PP
PLoS One; 2022; 17(2):e0263214. PubMed ID: 35130291
[TBL] [Abstract][Full Text] [Related]
15. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Feldman SR; Reznichenko N; Berti F; Duijzings P; Ruffieux R; Otto H; Haliduola HN; Leutz S; Stroissnig H
Expert Opin Biol Ther; 2023; 23(8):759-771. PubMed ID: 37435850
[TBL] [Abstract][Full Text] [Related]
20. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
